Ratiopharm Gmbh

Sandra Brueck

Ganesh Vinayak Gat

Jana Pätz

Jana Paetz

Katrin Rimkus

Frank Muskulus

Julia Schulze Nahrup

Dominique Meergans

Rainer Alles

Dirk Fischer

Gertraud Koellner

Peter Kraass

Javed Hussain

Winfried Ness

Gertrud Auer

Yogesh S Deshpande

Birgit Schnitter

Dunja Kotschenreuther

Jutta Strohmeyer

Martin Koeberle

The present invention relates to prasugrel or a pharmaceutically compatible salt thereof, compositions that contain this active substance and pharmaceutical compositions that contain this active substance or a composition containing this active substance. The present invention further relates to methods for producing the novel compositions.

Prasugrel in non-crystalline form and pharmaceutical composition thereof

The invention concerns desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic 'R form', as well as a process for its production. In a second aspect, the invention concerns the desfesoterodine of the invention in a microencapsulated form.

Desfesoterodine in the form of a tartaric acid salt

The present invention relates to Prasugrel or a pharmaceutically acceptable salt thereof, compositions containing said active ingredient as well as pharmaceutical compositions containing said active ingredient or a composition containing said active ingredient. The present invention further relates to methods for the preparation of the novel compositions.

Prasugrel in micronized, crystalline form and pharmaceutical composition thereof

The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20&#xb0; C. to approx. 45&#xb0; C.

Process for the preparation of a medicament comprising vardenafil hydrochloride trihydrate

The present invention relates to a solid pharmaceutical dosage form comprising ticagrelor as pharmaceutically active ingredient, to certain particles of ticagrelor and to processes of preparing the same.

Solid pharmaceutical dosage form of ticagrelor

The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition.

Pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-quinazolinamine

The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one low-substituted hydroxypropyl cellulose.

Rapid release irbesartan-containing pharmaceutical composition

Growing community of inventors

Ottenhofen, Germany

Sandra Brueck